132 related articles for article (PubMed ID: 14614031)
21. Thalidomide and thrombosis.
Mehta P
Clin Adv Hematol Oncol; 2003 Aug; 1(8):464-5. PubMed ID: 16258433
[No Abstract] [Full Text] [Related]
22. Is thalidomide a true anti-angiogenic molecule in multiple myeloma?
Ribatti D; Vacca A
Haematologica; 2002 Apr; 87(4):344-5. PubMed ID: 11940476
[No Abstract] [Full Text] [Related]
23. Thalidomide: from teratogen to anti-angiogenic.
Grover JK; Vats K
Indian J Cancer; 2001 Mar; 38(1):22-32. PubMed ID: 14758882
[TBL] [Abstract][Full Text] [Related]
24. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM
Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811
[TBL] [Abstract][Full Text] [Related]
25. Extramedullary multiple myeloma escapes the effect of thalidomide.
Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
[TBL] [Abstract][Full Text] [Related]
26. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
[TBL] [Abstract][Full Text] [Related]
27. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
28. Total therapy 2 in treatment of multiple myeloma: questions about gene expression profiling and treatment-related mortality.
Mehta J
J Clin Oncol; 2011 Feb; 29(5):e124; author reply e125-6. PubMed ID: 21172887
[No Abstract] [Full Text] [Related]
29. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
30. [New treatment strategy of multiple myeloma for cure].
Murakami H; Handa H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
[TBL] [Abstract][Full Text] [Related]
31. [Thalidomide--new prospective therapy in oncology].
Pałgan K; Pałgan I
Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
[TBL] [Abstract][Full Text] [Related]
32. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
33. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Zangari M; Barlogie B; Anaissie E; Saghafifar F; Eddlemon P; Jacobson J; Lee CK; Thertulien R; Talamo G; Thomas T; Van Rhee F; Fassas A; Fink L; Tricot G
Br J Haematol; 2004 Sep; 126(5):715-21. PubMed ID: 15327525
[TBL] [Abstract][Full Text] [Related]
34. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Cibeira MT; Rosiñol L; Ramiro L; Esteve J; Torrebadell M; Bladé J
Eur J Haematol; 2006 Dec; 77(6):486-92. PubMed ID: 16978238
[TBL] [Abstract][Full Text] [Related]
35. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E
Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630
[TBL] [Abstract][Full Text] [Related]
36. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
[TBL] [Abstract][Full Text] [Related]
37. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma.
Sahebi F; Spielberger R; Kogut NM; Fung H; Falk PM; Parker P; Krishnan A; Rodriguez R; Nakamura R; Nademanee A; Popplewell L; Frankel P; Ruel C; Tin R; Ilieva P; Forman SJ; Somlo G
Bone Marrow Transplant; 2006 May; 37(9):825-9. PubMed ID: 16565743
[TBL] [Abstract][Full Text] [Related]
38. Thalidomide for the treatment of leptomeningeal multiple myeloma.
Yutaka H; Mariko Y; Shinichiro O; Kunihiko M; Yusuke T; Yasuo I
Eur J Haematol; 2006 Apr; 76(4):358-9. PubMed ID: 16519710
[No Abstract] [Full Text] [Related]
39. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
Wasser K; Moehler T; Neben K; Nosas S; Heiss J; Goldschmidt H; Hillengass J; Düber C; Kauczor HU; Delorme S
Rofo; 2004 Sep; 176(9):1285-95. PubMed ID: 15346264
[TBL] [Abstract][Full Text] [Related]
40. Two cases of bacterial meningitis accompanied by thalidomide therapy in patients with multiple myeloma: is thalidomide associated with bacterial meningitis?
Pasa S; Altintas A; Cil T; Ustun C; Bayan K; Danis R; Urakci Z; Tuzun Y; Ayyildiz O
Int J Infect Dis; 2009 Jan; 13(1):e19-22. PubMed ID: 18621563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]